Pharmaceutical composition comprising pimobendan
The invention relates to novel solid formulations comprising as pharmaceutically active compound pimobendan and to processes for producing such solid formulations. The invention furthermore relates to a method for manufacturing a medicament for the prevention and/or treatment of congestive heart failure, wherein the solid formulations according to the invention are used.
1. A method of treating congestive heart failure in a small mammal, comprising:
administering a therapeutically effective amount of a solid formulation to a small mammal in need thereof, wherein the solid formulation comprises a homogenous dispersion of:
pimobendan or a pharmaceutically acceptable salt thereof provided in an amount of 0.5 mg to 20 mg;
a polyvalent acid selected from the group consisting of citric acid, tartaric acid, an anhydride thereof and mixtures thereof, wherein the polyvalent acid is present in an amount of 2.5 percent to 10 percent by weight of said solid formulation, and wherein the solid formulation includes a weight ratio of 1:10 to 1:40 of pimobendan to polyvalent acid; and
a flavor acceptable to small animals, wherein the flavor is present in an amount of 5 to 30 percent by weight of said solid formulation.
2. The method of claim 1 , wherein the solid formulation is a tablet or a granule.
3. The method of claim 1 , wherein the small mammal is selected from the group consisting of dogs, cats and rabbits.
4. The method of claim 1 , wherein the solid formulation further comprises starch and lactose.
5. The method of claim 4 , wherein the starch is selected from the group consisting of native starch, gelatinized starch, partly gelatinized starch, starch powder, starch granules, chemically modified starch, swellable physically modified starch and mixtures thereof.
6. The method of claim 4 , wherein the starch is corn starch.
7. The method of claim 4 , wherein the lactose consists of coarse particles greater than 200 μm in size.
8. The method of claim 1 , wherein the solid formulation comprises 1.25 mg, 2.5 mg, 5 mg or 10 mg pimobendan, the polyvalent acid is 50 mg/g citric acid, the flavor suitable for small animals is artificial beef flavor, and the solid formulation further comprises lactose, corn starch, croscarmellose-sodium, polyvidone, colloidal anhydrous silica and magnesium stearate.
9. A method of treating congestive heart failure in a small mammal, comprising:
administering a therapeutically effective amount of a solid formulation to a small mammal in need thereof, wherein the solid formulation comprises a homogenous dispersion of
pimobendan or a pharmaceutically acceptable salt thereof provided in an amount of 0.5 mg to 20 mg;
a polyvalent acid selected from the group consisting of citric acid, tartaric acid, an anhydride thereof and mixtures thereof, wherein the polyvalent acid is present in an amount of 2.5 percent to 10 percent by weight of said solid formulation, and wherein the solid formulation includes a weight ratio of 1:10 to 1:40 of pimobendan to polyvalent acid;
starch in an amount of 25 to 50 percent by weight of said solid formulation;
lactose in an amount of 25 to 50 percent by weight of said solid formulation; and
a flavor acceptable to small animals, wherein the flavor is present in an amount of 5 to 30 percent by weight of said solid formulation.
10. The method of claim 9 , wherein 1.25 mg, 2.5 mg, 5 mg or 10 mg of pimobendan is present in the solid formulation.
11. The method of claim 9 , wherein the solid formulation is a tablet or a granule.
12. The method of claim 9 , wherein the small mammal is selected from the group consisting of dogs, cats and rabbits.
13. The method of claim 1 , wherein the content uniformity of the pimobendan or the pharmaceutically acceptable salt thereof is 94.8 percent or greater.
14. The method of claim 13 , wherein the content uniformity of the pimobendan or the pharmaceutically acceptable salt thereof is at least 98.0 percent.
15. The method of claim 1 , wherein the solid formulation exhibits a dissolution profile, utilizing a paddle dissolution method at a rotation speed 75 RPM and a buffer pH of 4.0, in which a majority of the solid formulation has dissolved at 30 minutes.
16. The method of claim 9 , wherein the solid formulation exhibits a dissolution profile, utilizing a paddle dissolution method at a rotation speed 75 RPM and a buffer pH of 4.0, in which a majority of the solid formulation has dissolved at 30 minutes.
17. The method of claim 13 , wherein the content uniformity is blend uniformity.
18. The method of claim 9 , wherein the content uniformity of the pimobendan or the pharmaceutically acceptable salt thereof is 94.8 percent or greater.
19. The method of claim 1 , wherein the flavor is homogenously dispersed within the solid formulation.